George Yancopoulos, co-founder of biotech firm Regeneron, has purchased almost all of the condominium units in a mixed-use ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...

Regeneron is also expanding its Tarrytown, New York-based facility and building a separate facility in the state to expand capacity to fill injection pens - a process known as fill-finish.

Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will provide US-based manufacturing for Regeneron over the ... U.S. of about $4 billion in building world-class ...

Regeneron employee works on a pharmaceutical drug. Photo courtesy of Regeneron Pharmaceuticals HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron's biologic medicines and support high-paying jobs in the ...